Claire Bombardier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claire Bombardier has a total of 262 co-authors. Here are the top co-authors by number of shared publications:
Angela Cesta
Affiliation Toronto General Hospital Research Insitute, University Health Network, Toronto, Ontario, Canada
12 shared publications- Mohammad Movahedi
Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada
9 shared publications - Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
8 shared publications Xiuying Li
Affiliation Toronto General Hospital Research Insitute, University Health Network, Toronto, Ontario, Canada
7 shared publicationsMohammad Movahedi
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario; AND Institute of Health Policy, Management, and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada
5 shared publications- Brian Budgell
Canadian Memorial Chiropractic College, Toronto, Ontario, Canada
3 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by MDPI AG in Inflammation Journal
- Vol. 1 (1) , 2
Impact of Rheumatoid Arthritis Treatment Classes on Cardiovascular, Thromboembolic, Cancer Outcomes, and All-Cause Mortality: A Population-Based Cohort Study
Background: Rheumatoid arthritis (RA) is linked to increased risks of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, and mortality. However, differences in these risks by treatment class—particularly among older adults with cardiovascular (CVD) risk factors—remain unclear. Methods: We conducted a population-based cohort study using Ontario administrative data. Patients aged ≥67 years with incident RA (2008–2013) were followed through 2023. Outcomes included healthcare utilization for MACE and VTE, all-cause mortality, and cancer-related encounters. Time-varying treatment groups were: no csDMARD/advanced therapy (AT), glucocorticoids (GC) only, csDMARDs (reference), and biologic/targeted synthetic DMARDs (b/tsDMARDs). Weighted Fine–Gray models within a marginal structural framework were used, stratified by baseline CVD risk. Results: Among 10,058 patients, 80% had high CVD risk. Compared with csDMARDs, untreated patients (SHR 15.0; 95% CI 13.8–16.2) and GC users (SHR 1.29; 95% CI 1.13–1.47) had higher MACE risk, while AT use was associated with lower risk (SHR 0.53; 95% CI 0.37–0.77). Similar patterns were observed in low-risk patients. AT use was not associated with VTE. Untreated and GC users had increased mortality, whereas AT use reduced mortality. Increased cancer-related utilization was observed only in untreated patients. Conclusion: Treatment type strongly influences major outcomes in older adults with RA, underscoring the importance of integrating CVD and thrombotic risk into therapeutic decisions.
- 17 July 2026
- Published by MDPI AG in Inflammation Journal
- Vol. 1 (1) , 2
Open AccessImpact of Rheumatoid Arthritis Treatment Classes on Cardiovascular, Thromboembolic, Cancer Outcomes, and All-Cause Mortality: A Population-Based Cohort Study
Background: Rheumatoid arthritis (RA) is linked to increased risks of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, and mortality. However, differences in these risks by treatment class—particularly among older adults with cardiovascular (CVD) risk factors—remain unclear. Methods: We conducted a population-based cohort study using Ontario administrative data. Patients aged ≥67 years with incident RA (2008–2013) were followed through 2023. Outcomes included healthcare utilization for MACE and VTE, all-cause mortality, and cancer-related encounters. Time-varying treatment groups were: no csDMARD/advanced therapy (AT), glucocorticoids (GC) only, csDMARDs (reference), and biologic/targeted synthetic DMARDs (b/tsDMARDs). Weighted Fine–Gray models within a marginal structural framework were used, stratified by baseline CVD risk. Results: Among 10,058 patients, 80% had high CVD risk. Compared with csDMARDs, untreated patients (SHR 15.0; 95% CI 13.8–16.2) and GC users (SHR 1.29; 95% CI 1.13–1.47) had higher MACE risk, while AT use was associated with lower risk (SHR 0.53; 95% CI 0.37–0.77). Similar patterns were observed in low-risk patients. AT use was not associated with VTE. Untreated and GC users had increased mortality, whereas AT use reduced mortality. Increased cancer-related utilization was observed only in untreated patients. Conclusion: Treatment type strongly influences major outcomes in older adults with RA, underscoring the importance of integrating CVD and thrombotic risk into therapeutic decisions.
- Open Access
- 13 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0323229
Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study
Background: Herpes zoster (HZ) infection is a significant concern among seniors and immunosuppressed patients including those with rheumatoid arthritis (RA). We aimed to compare healthcare utilization (HCU) and mortality in RA patients with and without HZ. Methods: Patients from the Ontario Best Practices Research Initiative (OBRI) a clinical cohort (2008–2020) were linked to the Institute for Clinical Evaluative Sciences (ICES), a population health database. Each HZ patient was matched to four non-HZ patients based on sex, age, and HZ diagnosis date. The incidence of primary (HCU including hospitalization, Emergency Department (ED) visits, physician visits) and secondary (mortality and chronic clinical conditions) outcomes was calculated for each cohort, along with the impact of disease activity, patient-reported outcomes, and RA medication on these outcomes. Results: The study included 269 RA patients with and 1072 without HZ. At index date (HZ diagnosis) patients with HZ were less likely to have private health insurance (45.7% vs. 56.5%) and more prone to use biologics (30.9% vs. 26.8%) and JAK inhibitors (3.7% vs. 2.6%). Hospitalization/ED visits and mortality were higher in HZ patients, but these differences were not statistically significant after adjusting for other factors. HZ patients had significantly more physician visits (adj IRR: 1.17; 95% CI: 1.03–1.33). Female sex and lower CDAI were associated with fewer physician visits. JAK inhibitor use was associated with increased mortality (adj HR: 4.73, 95% CI: 1.68, 13.4). Conclusion: HCU was higher in RA patients with HZ, particularly in physician visits. Disease activity, patient reported outcomes and RA medication used did not have an impact on HCU and mortality.
- 13 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0323229
Open AccessHealthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study
Background: Herpes zoster (HZ) infection is a significant concern among seniors and immunosuppressed patients including those with rheumatoid arthritis (RA). We aimed to compare healthcare utilization (HCU) and mortality in RA patients with and without HZ. Methods: Patients from the Ontario Best Practices Research Initiative (OBRI) a clinical cohort (2008–2020) were linked to the Institute for Clinical Evaluative Sciences (ICES), a population health database. Each HZ patient was matched to four non-HZ patients based on sex, age, and HZ diagnosis date. The incidence of primary (HCU including hospitalization, Emergency Department (ED) visits, physician visits) and secondary (mortality and chronic clinical conditions) outcomes was calculated for each cohort, along with the impact of disease activity, patient-reported outcomes, and RA medication on these outcomes. Results: The study included 269 RA patients with and 1072 without HZ. At index date (HZ diagnosis) patients with HZ were less likely to have private health insurance (45.7% vs. 56.5%) and more prone to use biologics (30.9% vs. 26.8%) and JAK inhibitors (3.7% vs. 2.6%). Hospitalization/ED visits and mortality were higher in HZ patients, but these differences were not statistically significant after adjusting for other factors. HZ patients had significantly more physician visits (adj IRR: 1.17; 95% CI: 1.03–1.33). Female sex and lower CDAI were associated with fewer physician visits. JAK inhibitor use was associated with increased mortality (adj HR: 4.73, 95% CI: 1.68, 13.4). Conclusion: HCU was higher in RA patients with HZ, particularly in physician visits. Disease activity, patient reported outcomes and RA medication used did not have an impact on HCU and mortality.
- 1 March 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (6) , 543-552
Healthcare Utilization and Cost of Herpes Zoster Infection in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study
Objective: Patients with rheumatoid arthritis (RA) have an increased risk of developing herpes zoster (HZ) compared to the general population. We aimed to measure healthcare utilization (HCU) and related costs of HZ among patients with RA, from the public payer’s perspective. Methods: Adult patients with RA diagnosed with HZ between 2008 and 2020 were matched by sex, age, and date of HZ infection to (1) patients with RA without HZ, (2) the non-RA population with HZ, and (3) the non-RA population without HZ. Unadjusted gamma distribution models and generalized estimating equations were used to compare HCU costs and the number of clinical events (CEs), including hospital admissions and emergency department and physician visits, in patients with RA with HZ to each matched cohort. Results: We identified 15,573 patients with RA diagnosed with HZ and a similar number for each of the 3 matched cohorts. From year 1 to year 10, mean total cost ranged from CAD $13,507 to CAD $17,120 for the RA with HZ cohort compared to CAD $12,651 to CAD $14,534 in the RA without HZ cohort. Physician billing and inpatient hospital costs were the largest drivers of increased costs for all cohorts. Compared to patients with RA with HZ, each matched cohort experienced a significantly lower mean number of total CEs, with the highest difference in total CEs 1 year following an HZ infection. Conclusion: HCU and related costs were higher in patients with RA with HZ compared to patients with RA without HZ and non-RA populations with and without HZ. Treatment strategies that minimize the risk of HZ and encourage patients to keep up to date with vaccinations should be considered.
- 1 March 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (6) , 543-552
Healthcare Utilization and Cost of Herpes Zoster Infection in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study
Objective: Patients with rheumatoid arthritis (RA) have an increased risk of developing herpes zoster (HZ) compared to the general population. We aimed to measure healthcare utilization (HCU) and related costs of HZ among patients with RA, from the public payer’s perspective. Methods: Adult patients with RA diagnosed with HZ between 2008 and 2020 were matched by sex, age, and date of HZ infection to (1) patients with RA without HZ, (2) the non-RA population with HZ, and (3) the non-RA population without HZ. Unadjusted gamma distribution models and generalized estimating equations were used to compare HCU costs and the number of clinical events (CEs), including hospital admissions and emergency department and physician visits, in patients with RA with HZ to each matched cohort. Results: We identified 15,573 patients with RA diagnosed with HZ and a similar number for each of the 3 matched cohorts. From year 1 to year 10, mean total cost ranged from CAD $13,507 to CAD $17,120 for the RA with HZ cohort compared to CAD $12,651 to CAD $14,534 in the RA without HZ cohort. Physician billing and inpatient hospital costs were the largest drivers of increased costs for all cohorts. Compared to patients with RA with HZ, each matched cohort experienced a significantly lower mean number of total CEs, with the highest difference in total CEs 1 year following an HZ infection. Conclusion: HCU and related costs were higher in patients with RA with HZ compared to patients with RA without HZ and non-RA populations with and without HZ. Treatment strategies that minimize the risk of HZ and encourage patients to keep up to date with vaccinations should be considered.
- Open Access
- 15 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 940-941
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.
- 15 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 940-941
Open AccessCanadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.
- 1 August 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (9) , 1198-1199
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #1
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis, with a series of best practice statements and a recommendation for the choice of disease-modifying antirheumatic drug therapy after an inadequate response to tumor necrosis factor inhibitors (TNFi). These add to our prior recommendation for tapering of advanced therapy.1
- 1 August 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (9) , 1198-1199
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #1
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis, with a series of best practice statements and a recommendation for the choice of disease-modifying antirheumatic drug therapy after an inadequate response to tumor necrosis factor inhibitors (TNFi). These add to our prior recommendation for tapering of advanced therapy.1
- 14 May 2023
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry
Full Papers; Authors: N. Guo, X. Li, M. Movahedi, A. Cesta, C. Bombardier
- 14 May 2023
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry
Full Papers; Authors: N. Guo, X. Li, M. Movahedi, A. Cesta, C. Bombardier
- Open Access
- 19 November 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-10
Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
Background: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late-onset rheumatoid arthritis (LORA) is traditionally defined as the onset of RA after the age of 60 years. Compared to younger-onset rheumatoid arthritis (YORA) which occurs before the age of 60 years, LORA has unique characteristics and disease manifestations. To date, few reports have addressed LORA and the prognosis of LORA patients remains unclear. We compared the clinical characteristics, time to remission and treatment regimen at remission between LORA and YORA patients. Methods: This prospective cohort study used a registry database in Ontario, Canada from 2008 to 2020. Patients were included if they had active rheumatoid arthritis (RA) disease (≥1 swollen joint) and were enrolled within 1 year of diagnosis. LORA was defined as a diagnosis of RA in persons 60 years and older and YORA as a diagnosis of RA in persons under the age of 60. Remission was defined by Disease Activity Score 28 (DAS28) ≤2.6. A multivariable Cox proportional hazards model was used to estimate time to remission. Results: The study included 354 LORA patients and 518 YORA patients. The mean (standard deviation) baseline DAS28 score was 5.0 (1.3) and 4.8 (1.2) in LORA and YORA patients, respectively (p=0.0946). Compared to YORA patients, the hazard ratio for remission in LORA patients was 1.10 (95% confidence interval 0.90 to 1.34 p=0.36) after adjusting for other prognostic factors. For patients who reached remission, LORA patients were less likely to be on a biologic or Janus kinase (JAK) inhibitor (16% vs. 27%) and more likely to be on a single conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) (34% vs. 27%) than YORA patients (p=0.0039). Conclusion: LORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without a biologic or JAK inhibitor.
- 19 November 2022
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 24 (1) , 1-10
Open AccessLate-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative
Background: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late-onset rheumatoid arthritis (LORA) is traditionally defined as the onset of RA after the age of 60 years. Compared to younger-onset rheumatoid arthritis (YORA) which occurs before the age of 60 years, LORA has unique characteristics and disease manifestations. To date, few reports have addressed LORA and the prognosis of LORA patients remains unclear. We compared the clinical characteristics, time to remission and treatment regimen at remission between LORA and YORA patients. Methods: This prospective cohort study used a registry database in Ontario, Canada from 2008 to 2020. Patients were included if they had active rheumatoid arthritis (RA) disease (≥1 swollen joint) and were enrolled within 1 year of diagnosis. LORA was defined as a diagnosis of RA in persons 60 years and older and YORA as a diagnosis of RA in persons under the age of 60. Remission was defined by Disease Activity Score 28 (DAS28) ≤2.6. A multivariable Cox proportional hazards model was used to estimate time to remission. Results: The study included 354 LORA patients and 518 YORA patients. The mean (standard deviation) baseline DAS28 score was 5.0 (1.3) and 4.8 (1.2) in LORA and YORA patients, respectively (p=0.0946). Compared to YORA patients, the hazard ratio for remission in LORA patients was 1.10 (95% confidence interval 0.90 to 1.34 p=0.36) after adjusting for other prognostic factors. For patients who reached remission, LORA patients were less likely to be on a biologic or Janus kinase (JAK) inhibitor (16% vs. 27%) and more likely to be on a single conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) (34% vs. 27%) than YORA patients (p=0.0039). Conclusion: LORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without a biologic or JAK inhibitor.
- Open Access
- 7 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0274264
Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort
Objectives: Disease activity status described at fixed time points does not accurately reflect disease course in chronic and relapsing diseases such as rheumatoid arthritis (RA). We described longitudinal disease activity trajectories in early and established RA. Methods: Patients with available 28-Joint Disease Activity Score-erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAI) over two years were included. Using latent growth curve modelling (LCGM), subgroups of patients following distinct patterns were identified. Results: 1920 patients were included with 34.4% in early RA (< 2 years’ disease duration). Three subgroups were identified using DAS28-ESR in early RA: 1) low disease activity to remission (LDA-REM: 19.1%); 2) moderate disease to remission (MD-REM: 54%); 3) high to moderate disease (HD-MD: 26.9%). The HD-MD group had a significantly higher number of comorbidities, biologic and steroid use and lower post-secondary education. Using CDAI, we identified seven subgroups with only 1.9% remission in early RA. In established RA, seven subgroups were identified using either DAS28-ESR or CDAI. Using DAS28-ESR 27.8% with HD showed improvement in disease status (14.2% HD-REM, 10.3% HD-LDA and 3.3% HD-MD) while using CDAI 17.9% showed improvement. Conclusion: Disease course was different in early and established RA. Only 14.2% of established RA reached DAS28-ESR remission compared to 73.1% of early RA. Using CDAI only 1.9% of early RA and none of the established RA achieved remission, likely reflecting the impact of the patient global assessment on this score. Findings also illustrate the impact of sociodemographic characteristics and early treatment on disease course.
- 7 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0274264
Open AccessDisease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort
Objectives: Disease activity status described at fixed time points does not accurately reflect disease course in chronic and relapsing diseases such as rheumatoid arthritis (RA). We described longitudinal disease activity trajectories in early and established RA. Methods: Patients with available 28-Joint Disease Activity Score-erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAI) over two years were included. Using latent growth curve modelling (LCGM), subgroups of patients following distinct patterns were identified. Results: 1920 patients were included with 34.4% in early RA (< 2 years’ disease duration). Three subgroups were identified using DAS28-ESR in early RA: 1) low disease activity to remission (LDA-REM: 19.1%); 2) moderate disease to remission (MD-REM: 54%); 3) high to moderate disease (HD-MD: 26.9%). The HD-MD group had a significantly higher number of comorbidities, biologic and steroid use and lower post-secondary education. Using CDAI, we identified seven subgroups with only 1.9% remission in early RA. In established RA, seven subgroups were identified using either DAS28-ESR or CDAI. Using DAS28-ESR 27.8% with HD showed improvement in disease status (14.2% HD-REM, 10.3% HD-LDA and 3.3% HD-MD) while using CDAI 17.9% showed improvement. Conclusion: Disease course was different in early and established RA. Only 14.2% of established RA reached DAS28-ESR remission compared to 73.1% of early RA. Using CDAI only 1.9% of early RA and none of the established RA achieved remission, likely reflecting the impact of the patient global assessment on this score. Findings also illustrate the impact of sociodemographic characteristics and early treatment on disease course.
- Open Access
- 1 April 2022
- Published by Annals of Family Medicine
- Vol. 20 (Supplement) , 3259
The complexity of rheumatology: Patient characteristics presented during a telemedicine education program, ECHO rheumatology
Context Rheumatoid Arthritis (RA) is a common, chronic, and complex disease that affects 1% of the population in Ontario, with a higher prevalence in First Nations populations at 3%. Timely and aggressive treatment of RA with disease-modifying antirheumatic drugs (DMARDs) can lead to effective management of symptoms. Left untreated, however, RA can lead to deformed joints, debilitating pain, and significantly reduced quality of life. ECHO Rheumatology (‘ECHO’) was a program developed to address the burden of RA and other rheumatic diseases in Ontario. ECHO began running weekly sessions in January 2017. Objective This study describes the patient characteristics and quality improvement (QI) initiatives in ECHO. Study Design A mixed methods study with a QI lens Setting ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of medical education and care management, designed to increase capacity and access for care. In each weekly session, a healthcare provider (HCP) presents a patient case using a standardized patient case presentation form. Recommendations are then made from the interprofessional group and community. Population Studied Patient cases were summarized using the data extracted from HCPs’ weekly case presentation forms. QI opportunities were also identified from provider- and patient-level data. 1) Descriptive characteristics of patients presented and HCP participants 2) Differential diagnoses and recommendations following ECHO patient presentation Results From January 2017 to December 2019, ECHO provided 112 sessions with a total of 117 patient cases presented. 180 HCPs attended at least one session and 64 (36%) presented at least one case. At baseline, 63 (54%) of patients were female and mean age was 58 (range = 20-80). 24 (21%) patients had no diagnosis at baseline and 24 (21%) were on DMARDs. 27 (23%) were referred to a rheumatologist after presentation. Conclusions ECHO Ontario Rheumatology has gained uptake across Ontario. Patients presented at ECHO were complex, with multimorbidity, and reflected a mixture of classically inflammatory and mechanical pathologies mechanical pathologies, with relative prevalence reflecting the typical burden of rheumatologic and musculoskeletal diseases. Next steps in ECHO’s evaluation will address its impact on practice change through systematic follow up with participating health care providers, and on “real world” integration with preexisting models of care.
- 1 April 2022
- Published by Annals of Family Medicine
- Vol. 20 (Supplement) , 3259
Open AccessThe complexity of rheumatology: Patient characteristics presented during a telemedicine education program, ECHO rheumatology
Context Rheumatoid Arthritis (RA) is a common, chronic, and complex disease that affects 1% of the population in Ontario, with a higher prevalence in First Nations populations at 3%. Timely and aggressive treatment of RA with disease-modifying antirheumatic drugs (DMARDs) can lead to effective management of symptoms. Left untreated, however, RA can lead to deformed joints, debilitating pain, and significantly reduced quality of life. ECHO Rheumatology (‘ECHO’) was a program developed to address the burden of RA and other rheumatic diseases in Ontario. ECHO began running weekly sessions in January 2017. Objective This study describes the patient characteristics and quality improvement (QI) initiatives in ECHO. Study Design A mixed methods study with a QI lens Setting ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of medical education and care management, designed to increase capacity and access for care. In each weekly session, a healthcare provider (HCP) presents a patient case using a standardized patient case presentation form. Recommendations are then made from the interprofessional group and community. Population Studied Patient cases were summarized using the data extracted from HCPs’ weekly case presentation forms. QI opportunities were also identified from provider- and patient-level data. 1) Descriptive characteristics of patients presented and HCP participants 2) Differential diagnoses and recommendations following ECHO patient presentation Results From January 2017 to December 2019, ECHO provided 112 sessions with a total of 117 patient cases presented. 180 HCPs attended at least one session and 64 (36%) presented at least one case. At baseline, 63 (54%) of patients were female and mean age was 58 (range = 20-80). 24 (21%) patients had no diagnosis at baseline and 24 (21%) were on DMARDs. 27 (23%) were referred to a rheumatologist after presentation. Conclusions ECHO Ontario Rheumatology has gained uptake across Ontario. Patients presented at ECHO were complex, with multimorbidity, and reflected a mixture of classically inflammatory and mechanical pathologies mechanical pathologies, with relative prevalence reflecting the typical burden of rheumatologic and musculoskeletal diseases. Next steps in ECHO’s evaluation will address its impact on practice change through systematic follow up with participating health care providers, and on “real world” integration with preexisting models of care.
- 18 February 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (1) , 118-125
Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative
Full Papers; Authors: E. Rampakakis, C. Thorne, A. Cesta, M. Movahedi, X. Li, C. Mously, V. Ahluwalia, J. Brophy, P. Ciaschini, E. Keystone, A. Lau, G. Major, V. Pavlova, J.E. Pope, C. Bombardier
- 18 February 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (1) , 118-125
Medical cannabis use by rheumatology patients in routine clinical care: results from The Ontario Best Practices Research Initiative
Full Papers; Authors: E. Rampakakis, C. Thorne, A. Cesta, M. Movahedi, X. Li, C. Mously, V. Ahluwalia, J. Brophy, P. Ciaschini, E. Keystone, A. Lau, G. Major, V. Pavlova, J.E. Pope, C. Bombardier